2008

• The InflamaCORE team, the University of Miami and ZyVersa Therapeutics receive a grant from the Michael J. Fox Foundation to study the therapeutic benefits of IC100 in Parkinson's Disease. 
  

• The InflamaCORE team publishes article in the Journal Translational Research on the mechanism of action of IC100.
  
• The InflamaCORE team publishes article on the effects of IC100 on Brain Inflammaging.
  
  

• The InflamaCORE team and the University of Miami receive a grant from the NIH to study the effects of the inflammasome on Alzheimer's Disease after traumatic brain injury.
  

• The InflamaCORE team publishes article on the biomarker role of ASC in the early diagnosis of Alzheimer's Disease.
  
• The InflamaCORE team and Multiple Sclerosis (MS) expert from the University of Miami publish article in the Journal of Inflammation on the therapeutic benefits of IC100 in a clinically relevant animal model of MS.
  

2009

2014

2021

News

• The InflamaCORE team publishes article in the Journal of Cerebral Blood Flow and Metabolism on the anti-inflammatory effects of an anti-ASC antibody in a clinically relevant animal model of traumatic brain injury.
  

2019

• The InflamaCORE team publishes article in the Journal of Neuroscience characterizing the inflammasome in the CNS and on the anti-inflammatory effects of an anti-ASC antibody in a clinically relevant animal model of spinal cord injury.
  

• InflamaCORE receives the Global Health and Pharma Technology award 2021 as Leading Specialists in Inflammatory Disease Diagnostics & Treatments. 

2022

• InflamaCORE team obtains funds from the University of Miami to humanize a monoclonal antibody against the human ASC protein.

• The InflamaCORE team publishes article in the journal Glia characterizing the NLRP2 inflammasome in astrocytes.
  

• The InflamaCORE team and the University of Miami signs a sponsored research aggreement with ZyVersa Therapeutics, Inc to study the inflammasome in renal and metabolic diseases .

• The InflamaCORE team and the University of Miami receive a grant from the NIH to study the effects of the inflammasome on systemic inflammation after traumatic brain injury.
  
• The InflamaCORE funders are appointed to the Scientific Advisory Board of Zyversa Therapeutics, Inc.
  
• ZyVersa Therapeutics licenses InflamaCORE's intellectual property portfolio.
  
• InflamaCORE licenses inflammasome-related technology from the University of Miami.
  

2013

• InflamaCORE, LLC and the University of Miami obtain a fast track STTR grant from the NIH to develop IC100 for the treatment of spinal cord injury related inflammation

• InflamaCORE, LLC obtains funds from the Coulter Foundation to develop IC100 for the treatment of CNS-related inflammation.
  

2020